This podcast episode reviews recent advances in the treatment of IDH1-mutant acute myeloid leukemia (AML), focusing on the mechanisms, efficacy, and safety profiles of approved IDH1 inhibitors. The purpose is to present expert insights and clinical data from key trials that underscore the clinical benefits of these targeted therapies.

Acute myeloid leukemia (AML) is a heterogeneous malignancy characterized by diverse genetic mutations, including IDH1 and IDH2, which are present in approximately 15-20% of cases. Recent clinical practice guidelines, including the 2025 NCCN guidelines, emphasize the importance of comprehensive mutational profiling at diagnosis and at relapse to guide targeted treatment strategies for patients with refractory or relapsed (R/R) AML. IDH1-mutations, which occur in 5-7% of AML cases, result in the production of the oncometabolite 2-hydroxyglutarate (2-HG), disrupting cellular differentiation. IDH1-inhibitors, such as ivosidenib and olutasidenib, block this aberrant metabolic pathway, allowing for differentiation and apoptosis of leukemia cells. Given the rarity of these mutations, comprehensive molecular testing remains essential to optimize therapeutic decision-making.

Experts from Yale Cancer Center and MD Anderson Cancer Center describe the evolving landscape of molecular diagnostics in acute myeloid leukemia (AML). The discussion traces the shift from morphology- and immunophenotype-based classification to genomics-driven stratification, catalyzed by advancements in next-generation sequencing (NGS). Discussants emphasize the clinical importance of identifying key genetic mutations—such as FLT3, IDH1/2, TP53, NPM1, KMT2A, and NUP98—to inform prognosis and guide use of targeted therapies. They review the sensitivity and applications of testing modalities including Sanger sequencing, NGS, PCR, and capillary electrophoresis, and highlight how combining DNA and RNA analyses enhances detection of both mutations and gene fusions. Practical insights are offered on assay selection, test interpretation, and turnaround times, noting that while NGS is generally adequate for most targets, single-gene PCR may be needed for urgent decision-making. The episode concludes by underscoring the need for oncologists to partner with pathologists and review test coverage data to ensure appropriate molecular profiling. These insights support the integration of precise molecular diagnostics into routine AML management, enhancing personalized therapy and improving clinical outcomes.

Dr Boni Elewski, the James Elder Professor and Chair of Dermatology at the University of Alabama welcomes Dr Mark Lebwohl, who is the Dean for Clinical Therapeutics at the Icahn School of Medicine at Mount Sinai Waldman Department of Dermatology. They will be discussing generalized pustular psoriasis, or GPP, which is a chronic and potentially life-threatening inflammatory disease.

Dr Uwe Wollina, the former head of the department of dermatology and allergology at the Academic Teaching Hospital, Dresden welcome Drs. Merola and Amin to discuss the potential triggers of an acute GPP flare. GPP can be debilitating for patients, and they will discuss the different aspects of the burden of disease for patients with GPP.

Dr Jason Hawkes, a board-certified medical dermatologist in the Greater Sacramento area welcomes Drs. Bhutani and Reisner, to discuss the clinical presentation of GPP, the patient journey, diagnostic challenges, and novel management strategies from the perspective of the patient and provider.

Dr Stanley Cohen, and Mariah Z. Leach discuss some of the queries and concerns that patients may have about initiating or switching to treatment with a biosimilar for rheumatoid arthritis.

Dr Uwe Wollina, the head of the department of dermatology and allergology at the Academic Teaching Hospital, Dresden welcome Drs. Clive Liu and Eingun James Song, who are both dermatologists in Washington State to discuss their experiences in treating generalized pustular psoriasis, also referred to as GPP.

Dr Uwe Wollina, the head of the department of dermatology and allergology at the Academic Teaching Hospital, Dresden welcome Drs. Bhutani and Hawkes, both board-certified dermatologists in California to discuss their experiences in treating generalized pustular psoriasis, also referred to as GPP.

Dr John Kane, discusses negative symptoms in schizophrenia alongside fellow expert, Dr William Carpenter, and Mr Matthew Racher, a Certified Recovery Peer Specialist and dedicated advocate for people living with schizophrenia, who is currently studying for his Master of Social Work (MSW) in Miami, Florida.

Dr John Kane, a clinical expert in schizophrenia, discusses cognitive impairments in schizophrenia with fellow expert Dr Philip D. Harvey and patient advocate and mental health clinician, Mr Carlos Larrauri, who was diagnosed with schizophrenia.

In the final episode of Season 4, Dr Surya Bhatt is here to discuss the influence of continued smoking on COPD with Dr Richard Russell. They will discuss how smoking can impact treatment decisions, how we can get our patients to stop smoking and the effects smoking can have on COPD outcomes.

Dr Richard Russell is joined this week by Professor James Chalmers, the Asthma and Lung UK Chair of Respiratory Research at the University of Dundee, Scotland, and Honorary consultant physician at Ninewells Hospital, to discuss the role of the lung microbiome in respiratory disease and the influence it may have on the management of COPD

Dr Richard Russell is joined this week by Professor David Newby, the Chair of Cardiology at the University of Edinburgh, Scotland, to discuss the overlap between COPD and cardiovascular disease in clinical practice.

This week’s guest on the Medical Insider COPD podcast is Professor Eric Bateman, a Chest Physician and Professor of Respiratory Medicine at the University of Cape Town, South Africa. Join him and Dr Richard Russell as they discuss the barriers impeding implementation of global COPD recommendations in low- and middle-income countries (LMICs) and how global guidelines might better cater to LMICs highlighting the importance of treatment accessibility worldwide.

In this episode of the Medical Insider COPD podcast, Dr Richard Russell is joined by Professor Sinthia Bosnic-Anticevich to explore the importance of inspiratory effort in COPD

r Richard Russell is joined by Professor Antonio Anzueto in this episode of the Medical Insider COPD podcast to talk about real-world evidence and the gaps it can fill in the world of COPD research. Listen as they compare the finding from randomised controlled trials with real-world data and discuss how guidelines can be implemented in clinical practice.

Dr Richard Russell is joined by Professor James Chalmers once more to delve into the topic of bronchiectasis.

On the Medical Insider COPD Podcast this week, Dr Richard Russell is joined by Professor MeiLan Han from the University of Michigan in the United States. She will be discussing early COPD and how imaging can play a role in the diagnosis and management of COPD.

This episode’s guest on the Medical Insider COPD podcast is Dr Barbara Yawn, a primary care physician and COPD clinical researcher. Join her and Dr Richard Russell as they explore the impact of breathlessness from the patient perspective, discussing physical activity, pharmacotherapy and mortality.